Haisco Pharmaceutical Group revenue and financials
¥62.18Change from previous close: +0.40%Absolute change: +¥0.25
In the fiscal year ended December 2025, Haisco Pharmaceutical Group reported revenue of ¥4.39B (+17.91% year over year). Net income was ¥259.58M, a net margin of 5.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +17.91%
- 2025 vs 2024
- Net income growth
- −34.36%
- 2025 vs 2024
- Net margin
- 5.9%
- 2024: 10.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total assets | 7,877 | 7,660 | 7,011 | 6,992 | 6,925 |
| Current assets | 3,462 | 3,256 | 2,834 | 2,878 | 2,860 |
| Cash and equivalents | 1,847 | 1,810 | 1,386 | 1,457 | 1,298 |
| Short-term investments | 133 | 130 | — | — | — |
| Inventory | 351 | 328 | 307 | 300 | 317 |
| Net property, plant and equipment | 836 | 854 | 853 | 860 | 883 |
| Goodwill | 0.0 | — | — | — | — |
| Other intangible assets | 2,493 | 2,471 | 2,469 | 2,458 | 2,394 |
| Long-term investments | 111 | 138 | 139 | 89.1 | 94.2 |
| Current liabilities | 2,256 | 1,615 | 1,567 | 1,520 | 1,500 |
| Accounts payable | 272 | 157 | 166 | 165 | 175 |
| Long-term debt | 650 | 1,036 | 1,002 | 1,292 | 1,200 |
| Total debt | 2,264 | 2,237 | 1,980 | 2,313 | 2,209 |
| Total liabilities | 3,064 | 2,817 | 2,723 | 2,929 | 2,811 |
| Total equity (incl. minority) | 4,814 | 4,842 | 4,288 | 4,063 | 4,114 |
| Retained earnings | 2,185 | 2,246 | 1,691 | 1,574 | 1,643 |
| Minority interest | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |